Fusen Pharmaceutical Enhances Governance After Non-Compliance

Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.

Fusen Pharmaceutical Co., Ltd. has released supplemental information to their 2023 Corporate Governance Report, highlighting past non-compliance with certain Listing Rules related to reporting and disclosure of connected transactions. The company has since engaged an external consultant to review and address key internal control deficiencies, implementing remedial measures such as enhanced monitoring, training for staff and directors, and improved financial reporting systems.

For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.